Related Articles, Links







Entrez	PubMed	Nucleotide	Protein G	Senome	Structure	OMIM	PMC	Journals	E
Search	PubMed	for					Go Cle	ar.	
·		Limits	Preview/I	ndex	History	C	lipboard		Details
About Ent	rez								
		Display Abstrac	ct	Sho	w: 20 Sort	7	Send to	Text	₹
	,								

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy

Structure and function of milk allergens.

Wal JM.

☐ 1: Allergy. 2001;56 Suppl 67:35-8.

Laboratoire Associe INRA-CEA d'Immuno-Allergie Alimentaire, DRM-SPI Bat. 136 CEA de Saclay, 91191 Gif sur Yvette, France.

Proteins (CMP) involved in milk allergy are numerous and heterogeneous, with very few structural or functional common features. This heterogeneity is complicated by their genetic polymorphism, resulting in several variants for each protein. These variants are characterized by point substitutions of amino acids or by deletions of peptide fragments of varying size or by posttranslational modifications such as phosphorylation or glycosylation. All of these modifications may affect allergenicity. No common molecular structure can be associated with allergenicity, although some homologous regions such as casein phospho-peptides can explain an IgE cross-reactivity. Three-dimensional structure is an important feature in CMP allergenicity but denatured and linear epitopes are also involved. Epitopes are numerous and widely spread along the CMP molecule. They may be located in hydrophobic parts of the molecule where they are inaccessible for IgE antibodies in the native conformation of the protein but become bioavailable after digestive processes. Peptides as short as ca. 12-14 amino acid residues may account for a significant part of the allergenicity of the whole molecule, which justifies the need to be careful before proposing any CMP hydrolysate for highly allergenic children.

Publication Types:

- Review
- Review, Tutorial

PMID: 11298005 [PubMed - indexed for MEDLINE]

Display Abstract	Show	20	F	Sort F	Send to	Text	Ş
A Christian Viscouries	Snow:	1			47 - 47 - 47 - 47 - 47 - 47 - 47 - 47 -		178

Write to the Help Desk NCBI | NLM | NIH







PMC Journals В **OMIM** Structure Nucleotide Protein Genome PubMed Entrez ලා Clear Search PubMed for **Details** Clipboard Preview/Index Limits History **About Entrez** ed breed Text Ø Show: 20 Sort Sort Display Abstract

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

☐ 1: Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):125-7. Related Articles, Links

Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy.

Ferreira F, Hirthenlehner K, Briza P, Breiteneder H, Scheiner O, Kraft D, Breitenbach M, Ebner C.

Institute of Genetics and General Biology, University of Salzburg, Austria.

BACKGROUND: We analyzed the T cell activation potency and the IgEbinding properties (allergenicity) of nine isoforms of Bet v 1, the major allergen of birch pollen. METHODS: The capacity of recombinant Bet v 1 isoforms to bind serum IgE from allergic patients was evaluated by immunoblot experiments and skin prick tests. The potency of Bet v 1 isoallergens to activate T lymphocytes from birch-pollen-allergic patients was assayed using allergen-specific T cell clones. RESULTS: According to their ability to bind IgE from allergic patients in immunoblot experiments, Bet v 1 isoforms can be grouped into high-IgE-binding molecules and molecules with low/no IgE-binding activity. Representatively, isoform d was used in skin tests. Skin prick tests revealed no potency of this isoform to induce wheal and flare reactions in the skin of birch-pollen-allergic individuals. In contrast, isoform a and natural Bet v 1 displayed high allergenicity in vivo. On the other hand, Bet v 1 isoform d (low allergenicity) displayed significant higher T cell activation potency when compared to isoform a (high allergenicity). CONCLUSION: Based on these findings, we propose a new form of specific immunotherapy using hypoallergenic recombinant allergen isoforms.

PMID: 9130500 [PubMed - indexed for MEDLINE]

Display Abstract 🖂	Show: 20 🗷	Sort 💆	Send to	Text 💆

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer







				•					
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	E
Search Pu	ubMed	• for					Go Cl	ear	
P		Limits	Previ	ew/Index	History	CI	ipboard		Details
About Entrez		Display Abstr	act	Sho	w: 20 So	rt 🖳	Send to	Text	 \\
Text Version		□1: J Allergy	Clin Imm	unol. 1997	Jun;99(6 Pt 1):781-7.	Rela	ited Article	s, Links
Entrez Publ	Med		Clin Immu						

Mapping of IgE-binding epitopes on the recombinant major group I allergen of velvet grass pollen, rHol l 1.

Schramm G, Bufe A, Petersen A, Haas H, Schlaak M, Becker WM.

Forschungszentrum Borstel, Germany.

BACKGROUND: New and more successful approaches to diagnosis and therapy of allergic diseases require a more subtle understanding of the structure and the epitopes on the allergen molecule. OBJECTIVE: This study was done to obtain more information on the structure and the IgEbinding epitopes of a major allergen of velvet grass pollen, Hol 1 1. METHODS: We cloned Hol l 1 from a complementary DNA library and performed B-cell epitope mapping with 21 recombinant fragments expressed as fusion proteins in Escherichia coli. The fragments were analyzed by Western blotting with sera from 50 different patients. RESULTS: The patients' sera individually recognized at least four different IgE-binding regions (amino acids 1 to 27, 61 to 76, 84 to 105, and 158 to 240). According to their binding patterns with these epitopes, they were divided into five groups. Most sera (92%) bound to the C-terminal peptide (158 to 240), which consists of more than 80 amino acids, whereas there was virtually no binding to smaller fragments covering this region. In contrast to the C-terminal peptide, the IgE-binding peptides on the N terminus and on the middle region of the molecule were of a smaller size (15 to 30 amino acids). CONCLUSIONS: The major group I allergen of velvet grass bears at least four different IgE-binding epitopes, which were individually recognized by sera from different patients. The C terminus represents the major IgE-binding region and contains at least one discontinuous IgE-binding epitope, whereas the N terminus and middle region of Holl1 seem to contain continuous IgE-binding epitopes.

PMID: 9215246 [PubMed - indexed for MEDLINE]

Display Abstract	Show: 20 Sort	Send to Text

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources **Order Documents NLM Gateway TOXNET** Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Privacy Policy